Genomics

Dataset Information

0

Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer


ABSTRACT: Standard cancer therapy targets tumor cells while not considering the possible collateral damage on the tumor microenvironment that could impair therapy response. Employing patient-derived tumor organoids and primary stroma cells or a novel murine rectal cancer model, we show that tumor cell-derived IL-1a polarizes cancer-associated fibroblasts (CAFs) towards a pro-inflammatory phenotype causing an elevated oxidative DNA damage mediated by reactive nitrogen species (NOS) and subsequently sensitizing iCAFs to a p53-mediated therapy-induced senescence, which triggers changes in matrisome composition culminating in chemoradiotherapy resistance and disease progression. Consequently, IL-1 inhibition, prevention of iCAF senescence or senolytic therapy sensitizes mice to irradiation. Importantly, rectal cancer patients with poor response to radiotherapy are characterized by an increased number of CAFs, a dominant inflammatory CAF gene signature as well as lower IL-1 receptor antagonist (IL-1RA) serum levels. Low baseline IL1RA gene expression predicts poor outcome while IL-1RA serum levels are associated with a single nucleotide polymorphism (SNP) in IL1RA (rs4251961 T/C). Moreover, conditioned supernatant from patient tumor organoids sensitizes fibroblasts to undergo radiation-induced senescence in an IL-1-dependent manner. Collectively, we unravel a critical role for inflammatory CAFs in cancer therapy and identify IL-1 signaling as an attractive target for stroma-repolarization and prevention of CAF senescence.

ORGANISM(S): Mus musculus

PROVIDER: GSE191093 | GEO | 2021/12/18

REPOSITORIES: GEO

Similar Datasets

2022-01-14 | GSE190003 | GEO
2022-01-14 | GSE190005 | GEO
2022-01-12 | GSE190826 | GEO
2022-02-08 | PXD020871 | Pride
2022-02-08 | PXD030422 | Pride
2023-08-12 | GSE156281 | GEO
| E-MTAB-5364 | biostudies-arrayexpress
2019-06-03 | GSE115295 | GEO
2023-03-11 | PXD023302 | Pride
2022-01-01 | GSE140530 | GEO